Study | Study design | Treatment | Sex (M/F) | Rockwood type (III/ V) | Injury to Surgery | Age (y)a | Time for implant removala | Follow-up (m)a | Outcome measures | Quality assessment |
---|---|---|---|---|---|---|---|---|---|---|
Yin 2018 [38] | RCT | HP only | 18/7 | 16/10 | <  6 weeks | 44.5 ± 12.3 | 12.9 ± 1.8 mo | 21.3 ± 2.0 | VAS/ASES/CMS/Karlsson score/ patient satisfaction | 3b |
CCHP | 20/6 | 14/11 | 46.3 ± 11.9 | 4.9 ± 1.2 mo | 19.9 ± 2.9 | |||||
Chang 2019 [39] | RCS | HP only | 16/10 | 12/14 | <  2 weeks | 50 (24–69) | 6 (3–12) mo | 11 (9–27.1) | VAS/UCLA/ASES/Return to work | 7c |
CCHP | 15/6 | 7/14 | 44 (21–81) | 6 (5–10) mo | 9.5 (9–11.4) | |||||
Liu 2020 [41] | RCS | HP only | – | 0/112 | <  2 weeks | 46 (19–75) | 102.8 (89–116) d | 6 (after implant removal) | VAS/CMS | 7c |
CCHP | – | 0/105 | 50 (18–62) | 101.3 (86–118) d | ||||||
Seo 2020 [42] | RCS | HP only | 38/9 | 26/21 | <  2 weeks | 44.6 ± 15.4 | 4.2 ± 0.7 mo | 18.7 ± 6.2 | ASES/KSS/CMS | 7c |
CCHP | 65/8 | 34/39 | 46.9 ± 12.6 | 4.0 ± 1.0 mo | 18.1 ± 4.8 | |||||
Chen 2021 [40] | RCS | HP only | 15/4 | 9/10 | <  4 weeks | 44.5 ± 15.4 | 5.3 ± 1.5 mo | 38.5 ± 24.9 | VAS/CMS/UCLA/Taft score | 8c |
CCHP | 13/6 | 10/9 | 46.4 ± 16.4 | 5.7 ± 1.6 mo | 2.6 ± 21.7 |